Charles Dadswell, who focuses on patent law, is the new general counsel at drug development firm BioDelivery Sciences International.

Dadswell worked most recently at GlaxoSmithKline. In 14 years at GSK, Dadswell held several different positions. His most recent job was vice president of U.S. intellectual property.

Dadswell also will serve as director of contracts management and intellectual property at BDSI.

“The expertise that Chuck brings in-house to BDSI will better enable us to protect our key intellectual property assets and developments and also help to ensure that we are implementing the proper IP strategies going forward,” said BDSI Chief Executive Officer Mark Sirgo.

BDSI is developing a number of pain-related treatments, including one targeting breakthrough cancer pain.